Cargando…
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
Delamanid and bedaquiline are two drugs approved to treat drug‐resistant tuberculosis, and each have been associated with corrected QT interval (QTc) prolongation. We aimed to investigate the relationships between the drugs' plasma concentrations and the prolongation of observed QT interval cor...
Autores principales: | Tanneau, Lénaïg, Karlsson, Mats O., Rosenkranz, Susan L., Cramer, Yoninah S., Shenje, Justin, Upton, Caryn M., Morganroth, Joel, Diacon, Andreas H., Maartens, Gary, Dooley, Kelly E., Svensson, Elin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474693/ https://www.ncbi.nlm.nih.gov/pubmed/35687528 http://dx.doi.org/10.1002/cpt.2685 |
Ejemplares similares
-
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022) -
Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2020) -
Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2021) -
Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
por: van Beek, Stijn W, et al.
Publicado: (2022) -
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)